Skip to main navigation
  • About
    • Our Mission
    • Core Values
    • Leadership
    • Partners
  • CRISPR/Cas9
    • What’s CRISPR/Cas9?
    • How CRISPR/Cas9 Works
    • Types of Edits
    • Glossary
  • Programs & Pipelines
    • Full-Spectrum Approach
    • Our Pipeline
    • In Vivo Therapies
    • Ex Vivo Therapies
  • Patients & Families
    • Our Commitment
    • Clinical Trials
    • Community Perspectives & Resources
    • Expanded Access Policy
  • Healthcare Professionals
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications & Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
  • Full-Spectrum Blog
  • Contact
logo
  • Full-Spectrum Blog
  • Contact
  • About
    • Our Mission
    • Core Values
    • Leadership
    • Partners
  • CRISPR/Cas9
    • What’s CRISPR/Cas9?
    • How CRISPR/Cas9 Works
    • Types of Edits
    • Glossary
  • Programs & Pipelines
    • Full-Spectrum Approach
    • Pipeline
    • In Vivo Therapies
    • Ex Vivo Therapies
  • Patients & Families
    • Our Commitment
    • Clinical Trials
    • Community Perspectives & Resources
    • Expanded Access Policy
  • Healthcare Professionals
  • Investors & Media
    • Overview
    • Press Releases
    • Scientific Publications & Presentations
    • Corporate Deck
    • Events & Presentations
    • Press Kit
    • Corporate Governance
    • Financial Info
    • Stock Info
    • Analyst Coverage
    • Investor Resources
  • Careers
    • Life @ Intellia
    • Join Us
Investors & Media

Investors & Media

Investor Relations

  • Overview
  • Press Releases
  • Scientific Publications & Presentations
  • Corporate Deck
  • Events & Presentations
  • Press Kit
  • Corporate Governance
  • Financial Info
  • Stock Info
  • Analyst Coverage
  • Investor Resources

Stock Information

  

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases
Aug 04, 2022
Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Read More
Events & Presentations
Aug 4, 2022 8:00 AM EDT
Intellia Therapeutics Second Quarter 2022 Earnings Conference Call
US dial-in: 1-833-316-0545
International dial-in: 1-412-317-5726
All participants should ask to be connected to the Intellia Therapeutics conference call.
Add to Outlook
Add to Google Calendar
Click Here for Webcast
Contact IR Contact IR
Email Alerts
RSS Feeds
RSS Feeds
Print Page

Footer Links

  • Cookie Policy
  • Terms of Use
  • Privacy Policy

© Intellia Therapeutics, Inc. 2022

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.